T1002

Etodolac (AY-24236) inhibits the activity of cyclooxygenase I and II, thereby preventing the formation of prostaglandin which is involved in the induction of pain, fever, and inflammation. Etodolac is a pyranocarboxylic acid and non-steroidal anti-inflammatory drug (NSAID) with antipyretic and analgesic activities. It also inhibits platelet aggregation by blocking platelet cyclooxygenase and the subsequent formation of thromboxane A2.

1-Methyluric acid (1-Methylurate) acts on the bladder mucosa and increases the levels of insulin, triglycerides, cholesterol, and blood glucose.

Anticonvulsant agent 1 is a chemical compound with potent anticonvulsant properties.

1-Octanol, a saturated fatty alcohol, functions as an inhibitor of T-type calcium channels (T-channels), showing an inhibitory concentration (IC50) of 4 μM for native T-currents[1]. Additionally, 1-Octanol is recognized for its potential as a biofuel, possessing diesel-like properties[2].

1-Myristoyl-2-stearoyl-sn-glycero-3-phosphocholine is an endogenous metabolite. 1-Myristoyl-2-stearoyl-sn-glycero-3-phosphocholine is a non-limiting exemplary phosphatidyl choline.

1-Methylxanthine is a caffeine derivative. 1-Methylxanthine is an essential human urinary metabolite of caffeine and theophylline (1,3-dimethylxanthine, TP). 1-Methylxanthine enhances the radiosensitivity of tumor cells.

Tachykinin antagonist 1 is an antagonist of neurokinin receptors.

1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine is an endogenous metabolite identified in the aging mouse brain.

AT-1002 is a tight junction regulator and absorption enhancer. It is a 6-mer synthetic peptide.

AT-1002 TFA is a tight junction regulator and absorption enhancer. It is a 6-mer synthetic peptide.